Peginterferon beta-1a

Peginterferon beta-1a
Names
Trade namesPlegridy, Plegridy Pen
IUPAC name
  • 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)
Clinical data
Drug classImmunomodulator[1]
Main usesMultiple sclerosis[1]
Side effectsHeadache, muscle pain, flu-like symptoms, fever, weakness, redness, pain or itching at the injection site[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: D[3]
  • US: C (Risk not ruled out)[3]
    Routes of
    use    		Subcutaneous injection
    Typical dose125 ucg[4]
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa614059
    Legal
    License data
    Legal status
    • US: ℞-only [4]
    • EU: Rx-only [2]
    • In general: ℞ (Prescription only)
    Chemical and physical data
    FormulaC913H1417N246O256PS7 [C2H4O]n
    Molar mass44 000 g·mol−1

    Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.[1] It is specifically used for the relapsing forms including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.[4] It is given by injection under the skin.[1]

    Common side effects include headache, muscle pain, flu-like symptoms, fever, weakness, and redness, pain or itching at the injection site.[2] Other side effects may include liver problems, depression, seizures, heart failure, and anaphylaxis.[1] There are concerns with use in pregnancy.[5] How it works is not entirely clear; however it is believed to suppress the immune system.[2] It is made from interferon beta-1a joined with polyethylene glycol.[2]

    Peginterferon beta-1a was approved for medical use in the United States and Europe in 2014.[2][1] In the United States it costs about 7,500 USD for 4 weeks of medication as of 2021.[6] This amount in the United Kingdom costs the NHS about £650.[7]

    Medical uses

    In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[4]

    In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.[2]

    Dosage

    It is given at a dose of 125 ucg every two weeks.[4] A smaller dose of 94 ucg may be used for the first two shots.[4]

    References

    1. 1 2 3 4 5 6 "Peginterferon Beta-1a Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 27 October 2021.
    2. 1 2 3 4 5 6 7 "Plegridy EPAR". European Medicines Agency (EMA). Archived from the original on 26 June 2020. Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    3. 1 2 "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Archived from the original on 26 June 2020. Retrieved 25 June 2020.
    4. 1 2 3 4 5 6 "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Archived from the original on 26 June 2020. Retrieved 25 June 2020.
    5. ↑ "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. Archived from the original on 26 June 2020. Retrieved 27 October 2021.
    6. ↑ "Plegridy Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 April 2021. Retrieved 27 October 2021.
    7. ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 897. ISBN 978-0857114105.
    Identifiers:
    • "Peginterferon beta-1a". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-06-27. Retrieved 2020-10-17.
    • Plegridy at the US National Library of Medicine Medical Subject Headings (MeSH)
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.